GBS Inc GBS

iamphatboy

$GBS Bio stock Real-time Saliva Glucose & Saliva SARS-CoV-2 Antibody test Eliminates finger pricks and blood tests Large cash runway through most of 2022 Oversold Low Float

KozakHlib

Contextual immersion trading strategy idea. GBS Inc. operates as a biosensor diagnostic technology company. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4.98; stop-loss — $4.13. Information about take-profits will be...

Todoubled23

Heavily accumulated. Long term reversal in effect I am long at $2.88 looking for a $3.08 target price. Obv showing a change of character, volume obviously backing it up. Nice intraday trend reversal today (Friday the 6th). Holding for $3 daily pivot.

ego1smo

S @ 3.04 S <3.04 GBS is realy weak on TF 1D-1W. There is a big downtrend, and there is a signal on 1D + 1W, where candles closed under LVL 3.04. So i can expect selling pressure to 2.50. To avoid this scenario price should go higher than 3.18, but until this happened - we can try to use short signal from 1W.

Toro138

Easy 15% gain with very little risk involved

HorizontalPriceLevelsTrading

Glucose Biosensor Systems (Greater China) Holdings Inc is a United States based company engaged in manufacturing of Saliva Glucose Biosensor (SGB). SGB uses saliva to measure glucose non-invasively. The Saliva Glucose Test consists of the SGB which is a single use disposable saliva biosensor and the software app that interfaces the SGB with its digital information...

SmoothJB

Gbs Inc (NASDAQ:GBS) It's becoming apparent investors are slowly starting to catch onto this small undervalued bio stock. I think this recent IPO play is trading at great risk/reward prices. The risk of continued downside, while obviously always a factor to be present, is a lot less than the possibility of a sharp oversold rally or bounce at current prices. Buying...

DaferAli

It is expected that the stock will move up and form a new peak above the IPO price With a stop loss placed below the entry price by 10%